Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes

International Journal of Gynecological Pathology

Volumn 17, Issue 4, 1998, Pages 320-326

  Kallakury, Bhaskar V S ^a,b   Ambros, Robert A ^a   Hayner Buchan, Alida M ^a   Sheehan, Christine E ^a   Malfetano, John H ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinoma; Cell proliferation proteins; Cyclins; Endometrium; Immunohistochemistry; p120

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLINE; GLYCOPROTEIN GP 120; KI 67 ANTIGEN; PROTEIN KINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0031696540     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199810000-00005     Document Type: Article

References (55)

1. Draetta G, Luca F, Westendorf J, Brizuela L, Ruderman J, Beach D. Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF. Cell 1989;56:829-38.
2. Gautier J, Minshall J, Lohka M, Hunt T, Maller J. Cyclin is a component of MPF from xenopus. Cell 1990;60:487-94.
3. 2 for control of mitosis in fisson yeast. Nature 1981;292:558-60.
4. Draetta G, Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell-cycle-dependent phosphorylation and subunit rearrangement. Cell 1988;54:17-26.
5. Welch PJ, Wang JYJ. Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Natl Acad Sci USA 1992; 89:3093-7.
6. Krek W, Nigg EA. Structure and developmental expression of the chicken cdc2 kinase. EMBO J 1989;8:3071-8.
7. Lee MG, Norbury CJ, Spurr NK, Nurse P. Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein. Nature 1988;333:676-9.
8. CDC2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 1993;53:36-41.
9. CDC2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997; 80:753-63.
10. CDC2 cyclin dependent kinase protein overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998;16:1302-9.
11. 1 cyclins. Cell 1993;73:1059-65.
12. 1 phase progression: cyclin on cue. Cell 1994;79: 551-5.
13. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as masters of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA 1995;92:5386-90.
14. Shiozawa T, Xin L, Nikaido T, Fujii S. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecol Pathol 1997;16: 348-53.
15. 1 phase. Cancer Res 1988;48:1244-51.
16. Freemen JW, McGrath P, Bondada V, et al. Prognostic significance of proliferation associated nucleolar antigen p120 in human breast carcinoma. Cancer Res 1991;51:1973-8.
17. Fonagy A, Swiderski C, Wilson A, Bolton WE, Kenyon N, Freeman JW. Cell cycle regulated expression of nucleolar antigen p120 in normal and transformed human fibroblasts. J Cell Physiol 1993; 154:16-27.
18. Fonagy A, Swiderski C, Ostrovsky AM, Bolton WE, Freeman JW. Effect of nucleolar p120 expression level on the proliferation capacity of breast cancer cells. Cancer Res 1994;54:1859-64.
19. Freeman JW, Hazlewood JE, Bondada V, et al. Proliferation-related nucleolar antigens p145 and p120 associated with separate nucleolar elements and differences in tissue distribution. Cancer Communications 1989;1:367-72.
20. Ueki T, Nakayama Y, Sugaro Y, et al. Significance of the expression of proliferation-associated nucleolar antigen p120 in human colorectal tumors. Hum Pathol 1997;27:74-9.
21. Gerdes J, Li L, Schloeter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
22. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
23. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwag U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
24. Saski K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84.
25. Bravo K, Frank R, Blunddell PA, Mac Donald-Bravo H. Cyclin PCNA is the auxiliary protein of DNA polymerase J. Nature 1987; 326:515-7.
26. Wada T, Shimabukuro T, Matsuyama H, Nonito K, Skog S, Tribukait B. Optimal condition of fixing for immunohistochemical staining of proliferating cell nuclear antigen in tumor cells and its cell cycle related immunohistochemical expression. Cell Prolif 1994;27:541-51.
27. FIGO. Corpus cancer staging. Int J Gynecol Obstet 1989;28: 190-1.
28. Hendrickson M, Ross J. Eitel P. Martinez A, Kempson R. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
29. Ambros R, Ballouk F, Malfetano J, Ross JS. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994;18:569-75.
30. Scalzo DA, Kallakury BVS, Gaddipati RV, Sheehan CE, Keys HM, Savage D, Ross JS. Cell proliferation rate by MIB-1 immunohistochemistry predicts post-radiation recurrence in prostatic adenocarcinomas. Am J Clin Palhol 1998;109:163-8.
31. Cox DR. Regression models and life tables. J R Stat Soc 1972;32: 187-98.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-81.
33. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
34. Deligdisch L. Morphologic correlates of host response in endometrial carcinoma. Am J Reprod Immunol 1982;2:54-7.
35. Ambros RA, Sheehan CE, Kallakury BVS, Ross JS, Malfetano J, Paunovich E, Figge J. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996; 9:1165-9.
36. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 Gene mutations are common in uterine serous carcinomas and may occur as an early event in their pathogenesis. Am J Pathol 1997;150:177-85.
37. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
38. Perlaky L, Valdez BC, Busch RK, et al. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res 1992;52: 428-36.
39. Fonagy A, Swiderski C, Dunn M, Freeman JW. Antisense mediated specific inhibition of p120 protein expression prevents G1 to S-phase transition. Cancer Res 1992;52:5250-6.
40. McGrath PC, Holley DT, Hamby LS, Mattingly CA, Freeman JW. Prospective study correlating p120 antigen expression with established prognostic factors in breast cancer. Surg Oncol 1994;3:69-77.
41. Fonagy A, Swiderski C, Freeman JW. Altered transcription control is responsible for the increased control is responsible for the increased level of proliferation-associated p120 in rapidly growing breast carcinoma. Int J Cancer 1995;60:407-12.
42. O'Hanlan KA, Levine PA, Harbatkin D, Feiner C, Goldberg GL, Jones JG, Rodriguez-Rodriguez L. Virulence of papillary endometrial carcinoma. Gynecol Oncol 1990;37:112-9.
43. Symonds DA. Prognostic value of pathologic features and DNA analysis in endometrial carcinoma. Gynecol Oncol 1990;39:272-6.
44. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 1985;4:279-88.
45. Zaino RJ, Kurman RJ, Brunette VL, Morrow CP. Villoglandular adenocarcinoma of the uterus: a clinicopathologic study of 61 cases. [abstract]. Mod Pathol 1997;10:112A.
46. Nurse P. Ordering S phase and M phase in the cell cycle. Cell 1994;79:547-50.
47. Wang A, Yoshimi N, Suzui M, Yamauchi A, Tarao M, Mori H. Different expression patterns of cyclin A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 1996;122:122-6.
48. Wang J, Chenivesse X, Henglin B, Rorechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990;343:555-7.
49. Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, Nikaido T. Effect of tumor supressors on cell cycle-regulatory genes: Rb supresses p34 cdc2 expression and normal p53 supresses cyclin A expression. Exp Cell Res 1994;210:94-101.
50. Nordstrom B, Strang P, Bergstrom R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer 1996;78:1942-51.
51. Stendahl U, Strong P, Wagenius G, Bergstrom R, Tribulcit B. Prognostic significance of proliferation in endometrial carcinoma: a multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol 1991;10:271-84.
52. Wagenius G, Bergstrom R, Serang P, Gredesk, Rogo T, Tribuleait B. Prognostic significance of flow cytometric and clinical variables of flow cytometric and clinical variables in endometrial adenocarcinoma stages II. Anticancer Res 1991;11:2137-42.
53. Friberg L-G, Noren H, Delle U. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5 year survival study. Gynecol Oncol 1996;53:64-9.
54. Strang P, Stenkvist B, Rengstrom R, Stendahl U, Valdes del Campo M, Tribukait B. Flow cytometry in endometrial carcinoma: a comparative and prognostic study. Anticancer Res 1991;11: 783-8.
55. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A. Expression of cell cycle regulated proteins in prostate cancer. Cancer Res 1996;15:4159-63.